Clinical trial
A Phase 2A Multi Centre, Open Label, Pilot Study Of Pembrolizumab Added to The Standard First-Line Therapy Of Cyclophosphamide, Bortezomib And Dexamethasone (CyBorD) In Newly Diagnosed Multiple Myeloma Patients Not Eligible For Autologous Stem Cell Transplantation
NCT04258683 is registered in ClinicalTrials.gov with Canadian Myeloma Research Group as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2A Multi Centre, Open Label, Pilot Study Of Pembrolizumab Added to The Standard First-Line Therapy Of Cyclophosphamide, Bortezomib And Dexamethasone (CyBorD) In Newly Diagnosed Multiple Myeloma Patients Not Eligible For Autologous Stem Cell Transplantation
- Lead sponsor
- Canadian Myeloma Research Group
- Phase
- Phase 2
- Overall status
- Withdrawn
- Start date
- February 17, 2021
- Completion date
- October 31, 2022
- Enrollment
- 0 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.